Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Beigene has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.84, meaning that their average stock price is 284% ...

a PD-1 inhibitor marketed by BeiGene (NASDAQ:ONC) as Tevimbra. Last year, the PD-1/VEGF bispecific antibody developed by SMMT with its Chinese partner Akeso (OTCPK:AKESF) outperformed Merck’s ...